Treatment Guidelines for HIV‑Associated Cryptococcal Meningitis

Induction Therapy (first 2 weeks)

• Preferred regimen: Amphotericin B deoxycholate 0.7–1.0 mg/kg IV daily + flucytosine 100 mg/kg PO daily (divided q6 h) for 14 days in adults with HIV‑related cryptococcal meningitis. Evidence grade not specified. 1
• CSF sterilisation: The amphotericin B + flucytosine combination achieves sterile cerebrospinal fluid in 60–90 % of patients within 2 weeks. Evidence grade not specified. 2
• Effect of flucytosine on survival: Adding flucytosine does not improve immediate survival but significantly reduces the risk of disease relapse. Evidence grade not specified. 3
• Alternative for renal impairment: Liposomal amphotericin B 3–4 mg/kg IV daily or amphotericin B lipid complex 5 mg/kg IV daily for ≥2 weeks, reserved for patients with renal dysfunction or at high risk of nephrotoxicity. Evidence grade not specified. 1
• Fluconazole‑based alternative: Amphotericin B deoxycholate 0.7 mg/kg IV daily + fluconazole 800 mg PO daily for 2 weeks (used when flucytosine unavailable). Evidence grade not specified. 1

Consolidation Therapy (8–10 weeks)

• Standard consolidation: Fluconazole 400–800 mg PO daily for 8–10 weeks or until CSF cultures are sterile, following successful induction. Evidence grade not specified. [3][1]
• Inferior alternative: Itraconazole 400 mg PO daily may be used when fluconazole unavailable, but it provides lower efficacy and is supported by low‑quality evidence (C‑I). 1

Long‑Term Suppressive (Maintenance) Therapy

• Maintenance dose: Fluconazole 200 mg PO daily indefinitely until CD4 > 100–200 cells/µL is sustained on effective antiretroviral therapy (ART). Evidence grade not specified. 1
• Discontinuation criteria: Consider stopping suppressive fluconazole in patients with CD4 > 100 cells/µL, undetectable (or very low) HIV viral load for ≥3 months, and ≥12 months of prior antifungal therapy. 1
• Re‑initiation trigger: Restart maintenance fluconazole if CD4 falls below 100 cells/µL. 1

Management of Elevated Intracranial Pressure (ICP)

• Prevalence and mortality: Opening pressure > 25 cm H₂O occurs in up to 75 % of patients and is linked to 93 % of deaths within the first 2 weeks. Evidence grade not specified. 3
• Primary intervention: Perform daily therapeutic lumbar punctures to relieve symptomatic ICP elevation. Evidence grade not specified. 3
• Escalation: If daily lumbar punctures become intolerable or fail to control symptoms, consider placement of a CSF shunt (e.g., ventriculoperitoneal). Evidence grade not specified. 3
• Medication not recommended: Acetazolamide has no role in reducing ICP in cryptococcal meningitis. Evidence grade not specified. 3

Initiation of Antiretroviral Therapy (ART)

• Timing: Start ART 2–10 weeks after initiating antifungal induction therapy in HIV‑infected patients with cryptococcal meningitis. Evidence grade not specified. 1

Monitoring During Therapy

• Nephrotoxicity & electrolytes: Patients receiving amphotericin B require regular monitoring for dose‑dependent renal impairment and electrolyte disturbances (especially potassium and magnesium). Evidence grade not specified. 3
• Flucytosine therapeutic drug monitoring: In azotemic patients, measure serum flucytosine levels; peak concentrations (2 h post‑dose) should remain < 100 mg/L to avoid bone‑marrow suppression. Evidence grade not specified. 3

Common Pitfalls to Avoid

• Do not use cryptococcal antigen titres to dictate treatment decisions; rely on clinical response and CSF culture results. Evidence grade not specified. 3
• Never employ fluconazole monotherapy as initial treatment, even in patients perceived as low‑risk; pilot studies showed unsatisfactory outcomes. Evidence grade not specified. 2
• Define therapeutic failure as clinical deterioration despite appropriate therapy, lack of improvement after 2 weeks, or relapse after an initial response; repeat lumbar puncture is required for assessment. Evidence grade not specified. 3

Cryptococcal Meningitis Treatment in HIV-Positive Patients

Introduction to Treatment Guidelines

• The Centers for Disease Control and Prevention recommends a standard treatment consisting of induction therapy with amphotericin B combined with flucytosine for 2 weeks, followed by consolidation therapy with fluconazole for 8-10 weeks, and subsequent suppressive therapy with fluconazole 200 mg/day indefinitely until the CD4 count is >100-200 cells/µL in a sustained manner 4, 5

Induction Phase (First 2 Weeks)

• The preferred regimen is amphotericin B deoxycholate 0.7-1 mg/kg/day IV combined with flucytosine 100 mg/kg/day orally (divided into 4 doses) for 14 days, as recommended by the Infectious Diseases Society of America 4, 5, 6
• The combination of amphotericin B with flucytosine sterilizes the cerebrospinal fluid in 60-90% of patients within 2 weeks, according to the Clinical Infectious Diseases journal 7, 5
• The addition of flucytosine does not improve immediate survival but significantly decreases the risk of relapse, as stated by the MMWR Recommendations and Reports 4

Consolidation Phase (8-10 Weeks)

• After completing 2 weeks of successful induction: fluconazole 400-800 mg/day orally for 8-10 weeks or until cerebrospinal fluid cultures are sterile, as recommended by the Centers for Disease Control and Prevention 4, 5, 6

Suppressive Therapy (Long-Term Maintenance)

• After completing consolidation: fluconazole 200 mg/day orally indefinitely, as recommended by the Infectious Diseases Society of America 4, 5, 6
• Suppressive therapy should be continued until the patient has a CD4 count >100-200 cells/µL sustained with effective antiretroviral therapy, according to the MMWR Recommendations and Reports 4

Management of Elevated Intracranial Pressure

• Measuring opening pressure is crucial, and it should always be done in the initial lumbar puncture (patient in lateral decubitus position), as recommended by the Clinical Infectious Diseases journal 4, 8
• Elevated pressure (>25 cm H₂O) occurs in up to 75% of patients and is associated with 93% of deaths in the first 2 weeks, according to the MMWR Recommendations and Reports 4, 8

Special Considerations

• The regimen of fluconazole 400-800 mg/day plus flucytosine 150 mg/kg/day is effective but has significant toxicity (myelotoxicity, gastrointestinal) and is only recommended for patients who do not tolerate or do not respond to standard treatment, as stated by the Infectious Diseases Society of America 4, 9
• Never use fluconazole as initial monotherapy, even in "low-risk" patients, as pilot studies showed unsatisfactory results, according to the Clinical Infectious Diseases journal 7, 5, 6